Pulmonary Sarcoidosis Market is segmented by Mechanism of Action (Corticosteroid, Immunosuppressant, Antimalarial, Tumor Necrosis Factor-Alpha Inhibitors); by Drug Type (Corticotropin, Chloroquine, Dexamethasone, Colchicine, Prednisone, Methotrexate, Hydroxychloroquine, Azathioprine, Deltasone); by End User (Hospital Clinics, Surgical Centers, Diagnostic Centers, Others); By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Global Market Analysis, Trends, Opportunity and Forecast, 2023-2032

Pulmonary Sarcoidosis Market Overview

The global pulmonary sarcoidosis market was valued at USD 15.3 billion in 2023. The market is expected to expand at a CAGR of 10.8% from 2023-2032, and is expected to cross value of USD 47.2 billion by the end of 2032.

Pulmonary sarcoidosis means sarcoidosis in the lungs. It causes granulomas or small lumps of inflammatory cells in the lungs. Granulomas can affect the working of the lungs. The most common symptoms of pulmonary sarcoidosis are shortness of breath, chest pain, and wheezing. Pulmonary sarcoidosis mainly occurs due to the rising incidence of respiratory syndromes. Direct contact with smoke, dust, chemicals, and others, is the main cause of the disease. One of the major factors expected to add to the market growth of pulmonary sarcoidosis is the growing prevalence of the disease and therefore the need for preventive measures to treat it. Fresenius Umwelttechnik GmbH, Horizon Therapeutics plc, and Johnson & Johnson Services, Inc., are some of the significant parties in the market for pulmonary sarcoidosis.

                             Get More Insights on This Report - Request Free Sample PDF

Pulmonary Sarcoidosis Market Drivers

Some key drivers for the pulmonary sarcoidosis market are:

• Extensive Research on the Development of Advanced Drugs: The healthcare industry has continuously been working on the development of new drugs. One such major achievement related to the disease is the growing adoption of anti-tumor necrosis factor alpha antibodies and nonsteroidal anti-inflammatory drugs for treating pulmonary sarcoidosis.
• Rise in Prevalence of Respiratory Diseases: With the increasing prevalence of respiratory diseases worldwide, the need for drugs associated with pulmonary sarcoidosis is also expected to increase, thereby contributing to the market growth.
• Growing Use of Immunosuppressants and Corticosteroids: The development of immunosuppressants and corticosteroids for the treatment of pulmonary sarcoidosis has resulted in creating a pool of opportunities for the market players, which is expected to contribute significantly to the market growth.
• Broadening Investments for the Development of Drugs Related to the Disease: Both governmental and non-governmental organizations are increasingly working on raising their budgets for the research and development of drugs that would bring in new opportunities for expansion of the market for pulmonary sarcoidosis.

Pulmonary Sarcoidosis Market Challenges

Some challenges facing the Pulmonary Sarcoidosis market are:

• Long Process of Approval of Drugs: The process of drug approval for pulmonary sarcoidosis is very long. This, as a result, raises the overall cost of drug development, thereby hampering the interests of new players who want to work on researching new drugs for the disease.
• Treatment Complications: With the currently available treatments for pulmonary sarcoidosis, it has been observed that the patients who undergo the treatment often face several complications. As a result, there is a fear among the healthcare service providers as well as the patients for the available treatment, thereby impacting the demand for these treatments negatively.
• Lower Awareness Related to the Disease: Unawareness about the disease in several countries globally, which directly hampers the demand for treatment services for the disease, is also anticipated to lower the market growth in the coming years.

Pulmonary Sarcoidosis Market Segmentation

Segmentation of Pulmonary Sarcoidosis market are:

• By Mechanism of Action
  • Corticosteroid
  • Immunosuppressant
  • Antimalarial
  • Tumor Necrosis Factor-Alpha Inhibitors
• By Drug Type
  • Corticotropin
  • Chloroquine
  • Dexamethasone
  • Colchicine
  • Prednisone
  • Methotrexate
  • Hydroxychloroquine
  • Azathioprine
  • Deltasone
•  By End User
  • Hospital Clinics
  • Surgical Centers
  • Diagnostic Centers
  • Others
• By Region
  • North America (U.S., and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, Rest of Europe)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Middle East and Africa

Timeline considered for all these studies will be:

2023 – Base Year

2023 – Estimated Year

2023-2032 – Forecast Period

Pulmonary Sarcoidosis Market Regional Synopsis

The market for pulmonary sarcoidosis in Europe is anticipated to grab the dominating share in the coming years owing to the increasing prevalence of the disease among individuals, as well as the surge in the development of orphan drugs by the local market players for treating the disease.

Alternatively, the market for pulmonary sarcoidosis in North America is expected to grow at a rapid pace. The increasing number of drug approvals, followed by supportive policies to expedite the drug approval process, as well as the surge in healthcare expenditure in the region are some of the major factors projected to boost the market growth in North America.

Pulmonary Sarcoidosis Market Key Players

Some key players in the pulmonary sarcoidosis market are:

• Fresenius Umwelttechnik GmbH
• Horizon Therapeutics plc
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• Advenchen Laboratories, LLC
• Merck & Co., Inc.
• Bellus Health Inc.
• Novartis AG
• Adaptimmune Therapeutics Plc
• Pharmain Corp
• Firststring Research
• Epizyme, Inc
• Relief Therapeutics Holding SA
• Araim Pharmaceuticals Inc.
• Auven Therapeutics